Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Fujian Wanchen Biotechnology Group
300972
5
Pinlive Foods
300892
(FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Operating revenue | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 |
Cost of revenue | ||||||||||
Gross profit | ||||||||||
Operating expense | -15.62%36.32M | -29.27%7.36M | -3.24%10.18M | -31.60%8.68M | 7.17%10.1M | 3.29%43.05M | -44.71%10.41M | 44.52%10.52M | 79.00%12.7M | 11.12%9.42M |
Selling and administrative expenses | -9.99%13.76M | -3.75%2.83M | -17.10%3.37M | -11.40%4.16M | -5.18%3.39M | 24.84%15.28M | 10.31%2.94M | 39.13%4.07M | 40.84%4.69M | 7.86%3.58M |
-General and administrative expense | -9.99%13.76M | -3.75%2.83M | -17.10%3.37M | -11.40%4.16M | -5.18%3.39M | 24.84%15.28M | 10.31%2.94M | 39.13%4.07M | 40.84%4.69M | 7.86%3.58M |
Research and development costs | -18.72%22.57M | -39.33%4.53M | 5.51%6.8M | -43.44%4.53M | 14.72%6.7M | -5.67%27.76M | -53.79%7.47M | 48.14%6.45M | 112.80%8M | 13.22%5.84M |
Operating profit | 15.62%-36.32M | 29.27%-7.36M | 3.24%-10.18M | 31.60%-8.68M | -7.17%-10.1M | -3.29%-43.05M | 44.71%-10.41M | -44.52%-10.52M | -79.00%-12.7M | -11.12%-9.42M |
Net non-operating interest income expense | -65.65%-2.16M | -20.46%-591.78K | -66.31%-547.96K | -109.51%-512.76K | -112.99%-505.85K | -241.69%-1.3M | -55.30%-491.25K | -126.83%-329.48K | -428.31%-244.74K | -4,266.74%-237.5K |
Non-operating interest income | -13.37%2.51M | -26.27%503.94K | -9.82%666.77K | -10.05%675.21K | -8.29%668.9K | 210.42%2.9M | 13.38%683.54K | 193.33%739.4K | 906.95%750.65K | 12,695.46%729.34K |
Non-operating interest expense | 11.11%4.67M | -6.73%1.1M | 13.64%1.21M | 19.35%1.19M | 21.50%1.17M | 219.47%4.21M | 27.81%1.17M | 169.02%1.07M | --995.4K | --966.85K |
Other net income (expense) | ||||||||||
Income before tax | 13.23%-38.48M | 27.03%-7.95M | 1.13%-10.73M | 28.93%-9.2M | -9.77%-10.6M | -5.46%-44.35M | 43.05%-10.9M | -46.13%-10.85M | -84.39%-12.94M | -14.00%-9.66M |
Income tax | 38.18%-869.17K | 0 | 0 | 38.18%-869.17K | -17.28%-1.41M | 2 | 0 | -17.28%-1.41M | ||
Net income | 12.42%-37.61M | 27.03%-7.95M | 1.13%-10.73M | 27.80%-8.33M | -9.77%-10.6M | -5.11%-42.94M | 43.05%-10.9M | -46.13%-10.85M | -98.22%-11.53M | -14.00%-9.66M |
Net income continuous Operations | 12.42%-37.61M | 27.03%-7.95M | 1.13%-10.73M | 27.80%-8.33M | -9.77%-10.6M | -5.11%-42.94M | 43.05%-10.9M | -46.13%-10.85M | -98.22%-11.53M | -14.00%-9.66M |
Minority interest income | ||||||||||
Net income attributable to the parent company | 12.42%-37.61M | 27.03%-7.95M | 1.13%-10.73M | 27.80%-8.33M | -9.77%-10.6M | -5.11%-42.94M | 43.05%-10.9M | -46.13%-10.85M | -98.22%-11.53M | -14.00%-9.66M |
Preferred stock dividends | ||||||||||
Other preferred stock dividends | ||||||||||
Net income attributable to common stockholders | 12.42%-37.61M | 27.03%-7.95M | 1.13%-10.73M | 27.80%-8.33M | -9.77%-10.6M | -5.11%-42.94M | 43.05%-10.9M | -46.13%-10.85M | -98.22%-11.53M | -14.00%-9.66M |
Basic earnings per share | 25.90%-1.03 | 40.00%-0.21 | 17.14%-0.29 | 37.84%-0.23 | 6.25%-0.3 | 2.80%-1.39 | 47.76%-0.35 | -34.62%-0.35 | -85.00%-0.37 | 0.00%-0.32 |
Diluted earnings per share | 25.90%-1.03 | 40.00%-0.21 | 17.14%-0.29 | 37.84%-0.23 | 6.25%-0.3 | 2.80%-1.39 | 47.76%-0.35 | -34.62%-0.35 | -85.00%-0.37 | 0.00%-0.32 |
Dividend per share | ||||||||||
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |